A pill that quiets the inflammasome - MRT-8102 early data

Longevity.Technology · Article

Monte Rosa reported four-week data for MRT-8102, a once-daily oral molecular glue degrader that removes NEK7, a protein the NLRP3 inflammasome needs to assemble and fire. In 108 people with obesity and elevated cardiovascular risk, NEK7 fell by a median of roughly 80 to 90 percent at every dose, hsCRP fell by a median of 85 percent, IL-6 by 54 percent, and plaque-related signals calprotectin, S100A12 and SAA fell by medians of 56, 46 and 51 percent, with no serious adverse events reported.

Key takeaways:

• The target is upstream: degrading NEK7 aims to stop NLRP3 firing at its source rather than blocking one downstream cytokine at a time
• About 30 percent of participants carried NLRP3 risk alleles and started with higher inflammatory signals - an early hint at who might benefit most
• The next test is longer and harder: GFORCE-2, a six-month Phase 2b study in stable coronary artery disease with artery imaging, is planned for the first half of 2027

Hype check: Proven - target engagement and biomarker movement over four weeks in 108 people, company-reported with no peer-reviewed paper yet. Promising - durable, safe inflammasome suppression over years. Marketing - any framing of this as heart-attack prevention; no clinical outcomes were measured.